Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study
Clinical Kidney Journal · 31.10.2023 · 16 (11) · 2072-2081
DOI: 10.1093/ckj/sfad189 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Kidney Journal, online erschienen am 10.08.2023. Verfasst von Miho Murashima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nagoya City University, Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Background
Hyponatremia is associated with worse outcomes among patients with malignancy. However, contemporary cohort data on epidemiology and risk factors are lacking.
Methods
In this single-centre, retrospective cohort study, patients who received intravenous antineoplastic agents from 2018 to 2020 at Nagoya City University Hospital were enrolled. Associations of demographics, antineoplastic agents, types of malignancy and concomitant medications with hyponatremia, defined as serum sodium concentration ≤130 mmol/l, were analysed by mixed-effects logistic regression and the machine learning–based LightGBM model artificial intelligence technology.
Results
Among 2644 patients, 657 (24.8%) developed at least one episode of hyponatremia. Approximately 80% of hyponatremia was due to sodium wasting from the kidneys. Variables associated with hyponatremia both by mixed-effects logistic regression and the LightGBM model were older age, hypoalbuminemia and higher estimated glomerular filtration rate. Among antineoplastic agents, cisplatin {odds ratio [OR] 1.52 [95% confidence interval (CI) 1.18–1.96]}, pembrolizumab [OR 1.42 (95% CI 1.02–1.97)] and bortezomib [OR 3.04 (95% CI 1.96–4.71)] were associated with hyponatremia and these variables also had a positive impact on predicted hyponatremia in the LightGBM model.
Conclusions
Hyponatremia was common among patients with malignancy. In addition to older age and poor nutritional status, novel antineoplastic agents, including immune checkpoint inhibitors and bortezomib, should be recognized as risk factors for hyponatremia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
- Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Miho Murashima, Masahiro Tohkin
Förderung
- Nagoya City University
- Grant-in-Aid for Scientific Research
Zitieren
APA
Murashima, M., Ambe, K., Aoki, Y., Kasugai, T., Tomonari, T., Ono, M., Mizuno, M., Tohkin, M., & Hamano, T. (2023). Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study. Clinical Kidney Journal, 16(11), 2072-2081. https://doi.org/10.1093/ckj/sfad189
Vancouver
Murashima M, Ambe K, Aoki Y, Kasugai T, Tomonari T, Ono M, et al. Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study. Clinical Kidney Journal. 2023;16(11):2072-2081. doi:10.1093/ckj/sfad189
BibTeX
@article{Murashima2023,
author = {Murashima, Miho and Ambe, Kaori and Aoki, Yuka and Kasugai, Takahisa and Tomonari, Tatsuya and Ono, Minamo and Mizuno, Masashi and Tohkin, Masahiro and Hamano, Takayuki},
title = {Epidemiology and predictors of hyponatremia in a contemporary cohort of patients with malignancy: a retrospective cohort study},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {11},
pages = {2072--2081},
doi = {10.1093/ckj/sfad189}
}
EUVIMED